Tag: GlobeNewswire

Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company’s path forward following the FDA approval of LYTENAVA™

Access the segment here

ISELIN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it participated in a Virtual Investor “What This Means” segment featuring Kevin Lundquist, the Company’s recently appointed Chief Financial Officer

In the discussion, Mr. Lundquist shares his perspective on joining Outlook Therapeutics at such a pivotal time for the Company following the U.S. Food and Drug Administration approval of LYTENAVA, the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD). He also discusses the opportunity ahead as Outlook Therapeutics advances toward the commercial launch of LYTENAVA in the United States.

“Joining Outlook Therapeutics at this point in the Company’s evolution was a compelling opportunity,” said Kevin Lundquist, Chief Financial Officer of Outlook Therapeutics. “With FDA approval of LYTENAVA, we have entered an important new chapter as we transition into a commercial-stage company. I look forward to helping execute on our strategy, supporting the successful launch of LYTENAVA, and working to build long-term value for shareholders.”

The Virtual Investor “What This Means” segment is available to watch here.

About LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)

LYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the United States for the treatment of wet AMD. In the United States, LYTENAVA (bevacizumab-vikg) is the only ophthalmic formulation approved by the FDA. LYTENAVA (bevacizumab gamma) is also the subject of a centralized Marketing Authorization granted by the European Commission in the EU and Marketing Authorization granted by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the treatment of adults with wet AMD. In certain European Union Member States, LYTENAVA must receive pricing and reimbursement approval before it can be sold.

Bevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant humanized IgG1 monoclonal antibody specific to human vascular endothelial growth factor (VEGF). Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses endothelial cell proliferation, neovascularization, and vascular permeability. Inhibition of such activity targets a pathophysiologic process that contributes to vision loss.

Important Safety Information and Indication

LYTENAVA (bevacizumab-vikg) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).

Contraindications

LYTENAVA is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with a known hypersensitivity to bevacizumab products or any of the ingredients in LYTENAVA. Hypersensitivity reactions may manifest as severe intraocular inflammation.

Warnings and Precautions

Intravitreal injections have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering LYTENAVA. In addition, patients should be monitored following the injection to permit early treatment should an infection occur.

Increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA. Monitor intraocular pressure prior to and following intravitreal injection with LYTENAVA and manage appropriately.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LYTENAVA clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Adverse Reactions

The most common adverse reactions (≥1%) reported in patients receiving LYTENAVA were conjunctival hemorrhage (4%), eye pain (2%), and vitreous floaters (2%). These are not all the possible side effects of LYTENAVA.

You are encouraged to report side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Outlook Therapeutics at 1-833-999-OTLK (6855).

Please see the full U.S. Prescribing Information for LYTENAVA here.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA is the only ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.

Forward-Looking Statements

This press release contains statements that may or are considered “forward-looking statements”. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would”, the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, express or implied discussions regarding the Company’s planned launch of LYTENAVA in the United States and other jurisdictions and the timing thereof; expectations concerning potential revenue generation from sales of LYTENAVA; expectations surrounding market adoption of LYTENAVA; expectations regarding the potential impact of LYTENAVA in the retina community; Outlook Therapeutics’ development or future revenue plans for LYTENAVA generally; and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Current Report on Form 8-K filed with the SEC on August 12, 2026 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and future reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com

CEO Jan Goetgeluk to Meet with Institutional Investors Following 3X Omni One Order Growth and Expanding U.S. Government Adoption

AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — Virtuix Holdings Inc. (NASDAQ: VTIX), a leading developer of AI-driven, full-body simulation systems, today announced that Founder, Chief Executive Officer, and Chairman Jan Goetgeluk will highlight the Company’s recent consumer growth and expanding defense sales at the 2026 Maxim Growth Summit, being held October 13 and 14, 2026 at the Hard Rock Hotel New York.

Mr Goetgeluk’s meetings with institutional investors follow a series of recent commercial milestones across Virtuix’s consumer, defense, enterprise, and healthcare markets. Omni One consumer orders have been running at approximately 3X the prior-year level following the Company’s June launch of Omni One for Quest in collaboration with Meta. Virtuix has also completed its U.S. Air Force AFWERX Phase I SBIR program, expanded its work in counter-UAS and military training, and sold Omni One systems to the U.S. Department of Veterans Affairs and the U.S. Navy’s Morale, Welfare and Recreation (“MWR”) Program.

In enterprise and robotics, Omni One is being used in applications including humanoid robot teleoperation, with Tesla placing repeat Omni One Enterprise orders for its Optimus program and Figure AI also purchasing an Omni One Enterprise system.

Virtuix’s healthcare initiatives now include deployments and evaluation across the U.S. Department of Veterans Affairs, autism therapy for children, and rehabilitation applications, further extending the Omni technology platform beyond its original consumer gaming market.

“Virtuix is increasingly becoming much more than a consumer VR company,” said Jan Goetgeluk, Founder, Chairman and CEO. “The same full-body simulation platform is now gaining adoption across consumer entertainment, defense training, humanoid robotics, and healthcare. With consumer orders growing, government programs advancing, and enterprise customers placing repeat orders, I look forward to discussing our growth strategy and the opportunities ahead with institutional investors at the Maxim Growth Summit.”

Mr Goetgeluk is expected to discuss the commercial trajectory of the Omni platform, its adoption across consumer, defense, humanoid robotics, and healthcare markets, and the Company’s organic and strategic growth opportunities.

Maxim Growth Summit 2026
Dates: October 13 and 14, 2026
Location: Hard Rock Hotel New York, 159 West 48th Street, New York, NY 10036
Conference Website: Here
Format: One-on-One Investor Meetings
Attendees: Jan Goetgeluk, Founder, Chief Executive Officer, and Chairman

To schedule a one-on-one meeting with management at the Maxim Growth Summit 2026, please contact your Maxim Group representative. You may also email your request to VTIX@mzgroup.us or call Chris Tyson at (949) 491-8235.

About Virtuix

Virtuix Holdings Inc. (NASDAQ: VTIX) is a developer of AI-driven, full-body immersive simulation systems and the creator of the “Omni” omni-directional treadmill. Virtuix’s technology lets users physically move through virtual and AI-generated environments. The Company’s products are deployed across consumer entertainment, defense training and simulation, robotics, healthcare, research, and enterprise applications involving organizations including Meta, NASA, Tesla, KBR, and Sirica Therapeutics. The Company’s growing federal and defense footprint includes programs, deployments, and research initiatives involving the U.S. Army, Marine Corps, Navy, and Air Force.

Virtuix continues to expand the Omni brand from immersive entertainment into a broader, full-body simulation technology platform serving multiple commercial and government markets. For more information, visit virtuix.com or the Company’s new Investor Relations website at invest.virtuix.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “could,” “would,” “potential” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding the Company’s sales and expansion plans, plans to pursue strategic acquisitions, potential impacts on future revenues or shareholder value, and the Company’s position in the defense training market. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the Company’s ability to identify, negotiate, and complete acquisitions on favorable terms or at all; the ability to successfully integrate any acquired business; risks related to government contracting, including contract cancellations, modifications, or funding changes; the uncertainties related to market conditions; and other factors discussed in the “Risk Factors” section of the Company’s registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Visit Us on Social Media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X

Company Contact
Lauren Premo
Virtuix Inc.
press@virtuix.com

Investor Relations Contact
Chris Tyson
MZ Group
Direct: 949-491-8235
VTIX@mzgroup.us

Company and development partner Kopin have executed non-disclosure agreements with leading semiconductor and data center companies; technical discussions are underway ahead of hardware demonstrations planned for early 2027

NEW YORK, NY, Oct. 06, 2026 (GLOBE NEWSWIRE) — Fabric.AI (Nasdaq: FABC) (“Fabric.AI” or the “Company”), an AI infrastructure company developing a suite of fabless semiconductor technologies for next-generation AI factories, today announced that it has engaged Kearney, the global technology-focused management consulting firm, to apply its world-class infrastructure and supply chain expertise to accelerate and enhance the commercialization strategy for its Neural I/o™ MicroLED-based optical interconnect platform.

James Altucher, independent strategic advisor to Fabric.AI, commented, “Neural I/o™ addresses the two constraints that will define the next generation of AI data centers — how much data you can move, and what it costs in power to move it. We are already in confidential discussions with companies operating at the scale where those constraints bite hardest. Kearney’s role is to help us turn those conversations into commercial relationships, and to reach the semiconductor and infrastructure partners best positioned to bring this technology to market at scale. We anticipate active sales discussions beginning shortly after we demonstrate working hardware early next year.”

The engagement builds on confidential work already underway. Together with its development partner Kopin Corporation (Nasdaq: KOPN), Fabric.AI has executed non-disclosure agreements with several leading semiconductor and data center technology companies, and technical discussions with those counterparties are ongoing. Kearney’s mandate is to help Fabric.AI convert that early engagement into a structured commercial pipeline — sharpening product positioning, identifying and prioritizing target customers and channel partners, and preparing the Company for active sales discussions expected to begin following its planned hardware demonstrations in early 2027.

About Kearney

For 100 years, Kearney has been a leading management consulting firm and trusted partner to three-quarters of the Fortune Global 500 and governments around the world. With a presence across more than 40 countries, our people make us who we are. We work impact first, tackling your toughest challenges with original thinking and a commitment to making change happen together. By your side, we deliver—value, results, impact. Learn more at www.kearney.com.

About Fabric.AI

Fabric.AI (Nasdaq: FABC) is an AI infrastructure company developing a suite of fabless semiconductor technologies for next-generation AI factories, including its Neural I/o™ MicroLED-based optical interconnect platform.

About Kopin Corporation

Kopin Corporation (Nasdaq: KOPN) is a leading developer and provider of innovative display and application-specific optical solutions for defense, AI infrastructure, enterprise, professional and consumer products. Kopin’s portfolio includes microdisplays, display modules, eyepieces and projection assemblies, and vehicle- and head-mounted display systems built on Kopin’s liquid crystal, MicroLED and OLED display technologies, along with a range of optics and low-power custom silicon. Building on its patented bi-directional NeuralDisplay™ architecture, Kopin is also developing Neural I/o optical interconnects that use programmable MicroLED pixels as ultra-high-speed, low-power optical transceivers for AI data centers. For more information, please visit Kopin’s website at www.kopin.com.

Follow Kopin on LinkedIn, X and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the expected timing, demonstration and capabilities of the Neural I/o™ platform, the anticipated benefits and scope of the Company’s engagement with Kearney, and the progress, timing or outcome of confidential discussions with potential partners and customers. The existence of a non-disclosure agreement or of ongoing technical discussions does not constitute a commercial commitment, and there can be no assurance that any such discussion will result in a definitive agreement, a design win, or revenue. These statements are based on current expectations and are subject to risks and uncertainties — including development, integration and manufacturing risks — that could cause actual results to differ materially. Market and industry data are derived from third-party sources believed to be reliable but have not been independently verified by the Company. A discussion of these and other factors with respect to the Company is set forth in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

IR Contact:
CORE IR
212-644-0924
ir@fabric-ai.co 

Media Contact:
Fabric.AI
press@fabric-ai.co
www.fabricai.com 

Hong Kong, Oct. 06, 2026 (GLOBE NEWSWIRE) — Magic Empire Global Limited (NASDAQ: MEGL) (“MEGL” or the “Company”) today announced a new strategic initiative to expand into international commodity trading and supply chain finance, building on its established financial services platform in Hong Kong. Going forward, the Company intends to develop its business around two core pillars: commodity trading, focusing on mineral and energy resources, and financial services, centered on supply chain finance.

The Company has established a wholly-owned subsidiary in Hong Kong, Lunar Haste International Trading Limited, through which it is developing an integrated business comprising two complementary segments:

Commodity Trading: cross-border trading of timber, mineral and coal products, initially focusing on hardwood logs and sawn timber, iron ore, thermal coal and metallurgical coal, supplied to buyers in the United States, Europe and the Asia-Pacific region.

Supply Chain Finance: financing solutions for upstream suppliers and downstream buyers in the commodity sector, which may include pre-export financing, inventory and warehouse receipt financing, receivables financing, and letter of credit facilitation and related arrangements. Such financing solutions will be provided, where required, through licensed entities or in cooperation with licensed financial institutions, subject to applicable laws and regulations.

The Company has established a mature partnership network and supply chain resources across North America, Europe and Africa, including relationships with producers, mine operators, timber mills and end buyers. These resources are expected to provide the Company with stable access to supply and diversified sourcing channels from the outset of its trading operations.

The expansion is further anchored by the extensive industry experience of the Company’s management team, which has more than 30 years of experience in commodity trading and has held key management roles at a number of multinational commodity, mineral and energy trading companies.

The Company believes that combining physical trading with supply chain finance creates a mutually reinforcing model. Trading activities provide direct visibility into cargo flows, counterparty performance and collateral quality, which supports disciplined credit decisions, while financing capabilities strengthen relationships with suppliers and buyers and enhance the Company’s trading competitiveness.

“Our management team has spent more than 30 years building relationships across global commodity supply chains, and we have established a mature partnership network spanning North America, Europe and Africa,” said Mei Wang, CFO of MEGL. “By pairing that industry expertise with MEGL’s financial services capabilities, we can offer our partners both reliable trading channels and tailored financing. Commodity trading and supply chain finance will be the two pillars of MEGL’s growth going forward.”
The Company has completed its first commodity trading transaction through Lunar Haste International Trading Limited in the fourth quarter of 2026.

About Magic Empire Global Limited

Magic Empire Global Limited is a Hong Kong-based company engaged in financial services, including corporate finance advisory and underwriting services, and is expanding into international commodity trading and supply chain finance.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, including those regarding the Company’s expansion into commodity trading and supply chain finance, its dual core business strategy, and anticipated benefits, are based on current expectations and are subject to risks and uncertainties, including commodity price volatility; counterparty, credit and collateral risk associated with trading and financing activities; supply chain and logistics disruptions; compliance with timber legality and responsible sourcing requirements; sanctions and export control regulations applicable to mineral, energy and coal products; environmental and climate-related regulations and policies affecting coal; licensing requirements applicable to lending and financing activities; and other risks described in the Company’s filings with the SEC. Actual results may differ materially. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Contact
International Elite Capital
Annabelle Zhang
+1 (646) 866-7928
management@iecapitalusa.com

Everest Group recognizes TTEC’s CXM capabilities across vision and strategy, scope of services, innovation and investments, and global delivery

AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — TTEC, a leading global consulting, technology, and managed services company delivering solutions at the intersection of data, AI, and customer experience (CX), today announced it has been recognized by Everest Group for the sixth consecutive year in its Customer Experience Management (CXM) Services PEAK Matrix^® Assessment for the Americas. In the 2026 assessment, TTEC was positioned as a Major Contender in the Americas, and a Major Contender and Star Performer in EMEA.

The Everest Group assessment evaluates CXM providers across Market Impact and Vision & Capability, including vision and strategy, scope of services offered, innovation and investments, and delivery footprint. TTEC received strong evaluations across all these areas and placed among the top five providers in the Americas for Vision & Capability.

“TTEC continues to be positioned as a Major Contender in Everest Group’s Customer Experience Management (CXM) Services PEAK Matrix^® Assessment 2026 – Americas, supported by its broad CXM service portfolio, diversified enterprise client base, and combination of operational and technology expertise,” said Chhandak Biswas, Vice President, Everest Group. “Alongside TTEC Digital’s CX consulting and implementation capabilities, TTEC has invested in applying AI directly to frontline performance through areas such as simulation-based learning, coaching, knowledge support, and performance management. Its ability to combine these capabilities with scaled service delivery and high-touch support enables it to address both operational improvement and customer experience transformation.”

TTEC combines CX operations, technology, consulting, and AI-enabled services

TTEC’s CXM services span customer service, technical support, sales, order fulfillment and transaction processing, talent management, knowledge management, and customer retention. AI-enabled capabilities include proprietary solutions such as TTEC ADDI for voice translation, TTEC Let Me Know for agent knowledge support, and TTEC Perform for coaching and performance management.

“Customer experience is entering a new era in which AI must work alongside people, technology, and operations to deliver meaningful business results,” said John Abou, CEO of TTEC Engage. “Our focus is on helping clients connect those capabilities to improve customer interactions, strengthen operations, and create lasting value.”

The recognition extends across TTEC’s global CXM capabilities. In Everest Group’s 2026 EMEA CXM Services PEAK Matrix^® Assessment, TTEC was recognized as both a Major Contender and Star Performer. The Star Performer designation recognizes providers that demonstrate the greatest improvement from one assessment cycle to the next across the variables evaluated.

AI and technology integration are reshaping customer experience management

Everest Group reports that enterprises are moving beyond stand-alone generative AI tools toward integrated human-AI operating models and early agentic workflows, with greater emphasis on governance, integration, adoption, and measurable returns.

TTEC combines AI and technology with CX operations through a broad ecosystem spanning cloud, CRM, CCaaS, analytics, automation, conversational AI, workforce management, and knowledge management. Its technology ecosystem includes Microsoft, AWS, Google Cloud, Salesforce, Genesys, NICE, and Cisco, among others.

The Everest Group assessment is based on its annual request for information process, interactions with CXM service providers, client reference checks, and ongoing analysis of the CXM services market. The 2026 Americas assessment features 63 CXM service providers.

Read the full assessment to learn how TTEC’s CXM capabilities, AI-enabled solutions, technology expertise, and global delivery contributed to its recognition: TTEC Recognized by Everest Group for Sixth Consecutive Year in CXM Services PEAK Matrix^® Assessment for the Americas | TTEC

About TTEC
TTEC Holdings, Inc. (NASDAQ: TTEC) is a leading global consulting, technology, and managed services company delivering solutions at the intersection of data, AI, and customer experience. Serving iconic and disruptive brands, TTEC’s outcome-based solutions span the enterprise, touch every virtual interaction channel, and improve each step of the customer journey. TTEC Digital designs, builds, and operates omnichannel contact center technology, CRM, AI, and analytics solutions. The company also delivers AI-enhanced customer engagement, customer acquisition and growth, tech support, back-office, and fraud prevention services. Founded in 1982, TTEC brings technology and humanity together to deliver differentiated customer experiences and business results. The company’s employees operate on six continents. To learn more, visit ttec.com.

Disclaimer
Licensed extracts taken from Everest Group’s PEAK Matrix^® Reports may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix^® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix^® reports are independent, and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix^® Reports. 

Media Contact
Meredith Matthews
meredith.matthews@ttec.com

COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026, the annual meeting of American Society for Bone & Mineral Research being held in Boston from October 9-12, 2026. Updates include an oral presentation by Aliya Khan, M.D., of combined skeletal data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials showing normalization of bone mass and microarchitecture in clinical trial patients treated with TransCon^® PTH (palopegteriparatide) over a 5-year period.

“Our growing body of clinical trial data continues to illustrate the unique potential for our differentiated TransCon-based therapies to improve patient health and quality of life,” said Aimee Shu, M.D., Executive Vice President, Chief Medical Officer at Ascendis Pharma. “Compelling long-term data such as these help inform treatment paradigms focused on outcomes that matter most to patients, and we look forward to sharing additional results as our programs advance.”

Ascendis presentations at ASBMR 2026:

ORAL PRESENTATION
Hypoparathyroidism
Sunday, Oct. 11 Session: 11:30a.m.-12:30p.m. Presentation: 12:18 PM – 12:30 Calcium Homeostasis Disorders Ballroom A&B	ID #6080: Long-Term Effects of Palopegteriparatide on BMD and TBS in Adults With Chronic Hypoparathyroidism: Pooled Results from the PaTH Forward and PaTHway Trials Presented by Aliya Khan, M.D.
POSTERS
Hypoparathyroidism
Thursday, Oct. 8 5:30-6:30p.m. ASBMR/RBDA Pre-Meeting Symposium — Sunday, Oct. 11 2:00-3:00p.m. Poster Session II	ID #6680: Hypoparathyroidism: Understanding the Impact of Palopegteriparatide on Patients’ Health Related Quality of Life, Functioning, and Well-Being Presented by Meryl Brod, Ph.D.
Achondroplasia
Friday, Oct. 9 5:30-7:00p.m. Plenary Poster Session — Saturday, Oct. 10 2:00-3:30pm Poster Session 1	ID 6329: Improved Growth and Physical Functioning in Children with Achondroplasia Treated with Navepegritide in the ApproaCH Trial Open-Label Extension Presented by Ciara McDonnell, M.D.
Thursday, Oct. 8 5:30-6:30p.m. ASBMR/RBDA Pre-Meeting Symposium — Friday, Oct. 9 5:30-7:00p.m. Plenary Poster Session — Saturday, Oct. 10 2:00-3:30pm Poster Session I	ID 6320: Continued Improvements in Lower Extremity Alignment in Navepegritide-Treated Children With Achondroplasia: Week 104 Results from the ApproaCH Trial Presented by Leanne Ward, M.D.
Sunday, Oct. 11 2:00-3:00p.m. Late Breaking Poster Session II	Late Breaker ID 8736: Navepegritide Combined with Lonapegsomatropin for the Treatment of Children with Achondroplasia: 78-Week Results from the Phase 2 COACH Trial Presented by Ciara McDonnell, M.D.

About TransCon PTH
TransCon PTH (palopegteriparatide) is a prodrug of PTH (1-34), administered once daily, designed to provide stable levels of active PTH within the physiological range for 24 hours/day. TransCon CNP is approved as YORVIPATH^® in the United States (U.S.), European Union (EU), European Economic Area (EEA), and certain other jurisdictions as a treatment for adults with hypoparathyroidism.

About TransCon CNP
TransCon CNP (navepegritide) is a prodrug of C-type natriuretic peptide (CNP) administered once weekly, designed to provide continuous exposure of active CNP to receptors on tissues throughout the body to counteract the overactive FGFR3 signaling in achondroplasia. TransCon CNP is approved as YUVIWEL^® in the U.S. as a treatment for children with achondroplasia. Ascendis Pharma’s Marketing Authorisation Application for YUVIWEL is under review by the European Medicines Agency, with a decision anticipated in the fourth quarter of 2026.

About TransCon hGH
TransCon hGH (lonapegsomatropin) is a prodrug of somatropin administered once weekly, providing sustained release of active, unmodified somatropin. TransCon hGH is investigational in achondroplasia and is approved as SKYTROFA^® in the U.S., EU, EEA, and elsewhere for the treatment of growth failure in children due to growth hormone deficiency and in the U.S. for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

About Hypoparathyroidism
Hypoparathyroidism is an endocrine disease caused by insufficient levels of parathyroid hormone (PTH), the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidney and indirectly on the intestine. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for the majority of cases (70-80%), while other etiologies include autoimmune, idiopathic, and genetic causes, including ADH1.

About Achondroplasia
Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, causing serious muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia vary across different stages of life. Throughout infancy and childhood, observed complications include spinal abnormalities, enlarged brain ventricles, impaired muscle strength and stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; many of these persist or worsen in adulthood. These medical complications can affect physical well-being and quality of life, and may be impacted by a range of individual, clinical, and social factors. Some individuals with achondroplasia require multiple procedures and surgeries to address specific functional or anatomical concerns.

About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.

Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ planned oral presentation and posters at ASBMR 2026, (ii) the combined skeletal data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials, including normalization of bone mass and microarchitecture in clinical trial patients treated with TransCon PTH (palopegteriparatide) over a 5-year period, (iii) the unique potential for Ascendis’ highly differentiated TransCon-based therapies to improve patient health and quality of life, (iv) the potential for long-term data to help inform treatment paradigms focused on outcomes that matter most to patients, (v) Ascendis’ plan to share additional results as its programs advance, (vi) Ascendis’ clinical development activities, including the ApproaCH Trial open-label extension and the Phase 2 COACH Trial of navepegritide combined with lonapegsomatropin, (vii) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients and (viii) Ascendis’ use of TransCon to create new and potentially best-in-class therapies to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA^®, YORVIPATH^®, and YUVIWEL^® are trademarks owned by the Ascendis Pharma group. © October 2026 Ascendis Pharma A/S.

Investor Contact:	Media Contact:
Chad Fugere	Melinda Baker
Ascendis Pharma	Ascendis Pharma
+1 (650) 519-7494	+1 (650) 709-8875

Authorization follows more than $59 million of recent capital raised, with planned programs funded through targeted 2027 milestones

CHARLOTTE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — via IBN — Greenland Mines Ltd (“Greenland Mines” or the “Company”) (Nasdaq: GRML; FSE: HK6), a Greenland-focused critical-minerals developer, today announced that its Board of Directors has authorized a $20 million share repurchase program as part of an updated capital allocation strategy focused on advancing its core mineral projects, maintaining strong liquidity, and maximizing long-term shareholder value.

Following the Company’s recent raising of more than $59 million in new capital, Greenland Mines believes it is well positioned to fund planned work at Sarfartoq and Skaergaard through targeted 2027 milestones while maintaining the financial flexibility to opportunistically repurchase shares. The Company will continue to prioritize drilling, technical studies, metallurgy, environmental programs and permitting, while evaluating strategic investments and partnerships supporting its North Atlantic Critical Metals Corridor strategy.

“Our recent financings have given Greenland Mines the balance sheet to aggressively advance our world-class Greenland assets while preserving meaningful strategic flexibility,” said Bo Møller Stensgaard, President of Greenland Mines. “Our priority remains disciplined investment in Sarfartoq and Skaergaard. At the same time, we believe our own shares may represent a compelling use of capital at certain valuations. This $20 million authorization gives us the ability to act when we believe repurchases can create attractive long-term value for our shareholders.”

Under the authorization, the Company may repurchase up to $20 million of its outstanding common stock from time to time through open-market transactions or other permissible methods, including pursuant to trading plans established under Rules 10b5-1 and 10b-18, where applicable. The timing and amount of any repurchases will depend on market conditions, the Company’s share price, liquidity requirements, project funding needs and other capital allocation considerations. The authorization does not obligate the Company to repurchase any particular amount of common stock and may be modified, suspended or discontinued at any time.

About Greenland Mines Ltd
Greenland Mines Ltd is listed on Nasdaq and develops mineral assets in Greenland, including the Skaergaard precious-metals project in southeast Greenland and the Sarfartoq neodymium-praseodymium rare earths project in southwest Greenland. Its North Atlantic Critical Metals Corridor strategy seeks to connect Greenland resources with processing capacity and industrial customers in the United States and allied countries. The Company’s portfolio also includes a strategic investment in AnorTech, which is developing alumina and other materials from Greenland anorthosite.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “potential,” “could,” “may,” “will,” “should,” “estimate,” “objective” and similar expressions.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties. Many factors could cause actual results to differ materially, including exploration, resource-estimation, metallurgical, engineering, environmental, social, permitting, logistical, infrastructure, financing, commodity-price, market, counterparty and execution risks; the availability and level of participation of advisory board members; changes to planned programs and timelines; the Company’s ability to obtain required approvals and financing; and risks described in documents filed or to be filed with the U.S. Securities and Exchange Commission. No assurance can be given that studies, applications, partnerships, transactions, development decisions or production will occur on the timing contemplated or at all.

Readers should carefully consider these factors and the other risks and uncertainties described in the Company’s SEC filings. All information in this press release is provided as of its date, and the Company undertakes no obligation to update any forward-looking statement except as required by applicable law.

Investor Contact and Corporate Communications
ir@greenlandmines.com
www.greenlandmines.com

Corporate Communications
IBN
Austin, Texas
IBN.Ai | 512.354.7000 | Editor@IBN.Ai

Approval provides Rezolve Ai with capital allocation flexibility to advance towards planned repurchases while preserving capacity for growth, strategic M&A and other shareholder value initiatives

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — Rezolve Ai plc (NASDAQ: RZLV) (“Rezolve Ai” or the “Company”), a global leader in AI-powered commerce, today announced that it has received Court approval for the Company’s proposed capital reduction, an important step in enabling Rezolve Ai to implement its previously announced share repurchase program of up to $300 million.

The Court approval follows shareholder approval of the capital reduction and supports the Board’s objective of providing Rezolve Ai with greater flexibility to allocate capital in a manner that it believes best serves long-term shareholder value.

The Company expects to commence repurchases following the remaining procedural requirements necessary for the capital reduction to become effective having been completed, subject to market conditions, available capital, liquidity, capital allocation priorities, legal requirements and other relevant factors.

Under the Company’s proposed arrangements with BTIG, BTIG is expected to purchase ordinary shares in the market within agreed parameters, with Rezolve Ai repurchasing such shares from BTIG in accordance with applicable legal requirements and the terms of the program.

Daniel M. Wagner, Chairman and Chief Executive Officer of Rezolve Ai, said:
“Court approval of the capital reduction is an important milestone for Rezolve Ai and for our shareholders.

“We have consistently said that we believe the public market valuation of Rezolve Ai does not reflect the strength of our technology, the progress we have made commercially, or the scale of the opportunity ahead in AI-powered commerce.

“This approval gives us the flexibility to begin acting on that belief. Subject to completion of the remaining procedural steps and market conditions, we intend to commence repurchases where the Board believes doing so represents an attractive and disciplined use of capital.

“At the same time, we remain focused on growth. We continue to evaluate non-dilutive funding alternatives and strategic capital initiatives that could further enhance our flexibility over time, while preserving our ability to pursue strategic M&A, invest in the business and execute against our long-term plan.

“This is about confidence, discipline and shareholder value. We now have an important tool to act decisively and responsibly when we believe the market materially undervalues Rezolve Ai.”

The proposed repurchase program does not obligate the Company to acquire any specific number or dollar amount of shares, nor does it represent a commitment to deploy the full amount of the available capacity under the repurchase program. Any repurchases will be funded only from legally available funds and will remain subject to the Company’s liquidity position, capital allocation priorities, market conditions and applicable legal requirements. The program may be suspended, modified or discontinued at any time.

Further details regarding the capital reduction and share repurchase authority will be included in the Company’s public filings.

About Rezolve Ai
Rezolve Ai is a global leader in AI-powered commerce and engagement. Its technology helps retailers, brands, financial institutions and commerce platforms create intelligent, personalized customer experiences across search, discovery, engagement and transaction journeys.

Rezolve Ai’s platform is designed to connect consumers, merchants, banks and payment providers through intelligent commerce infrastructure that makes customer interactions more relevant, measurable and valuable. Through its AI-powered commerce capabilities and Reward’s financial engagement platform, Rezolve Ai is building the infrastructure for the next generation of personalized and agentic commerce.

Media Contact
Urmee Khan
Global Head of Communications
urmeekhan@rezolve.com
+44 7576 094 040

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the Company’s share repurchase program, the expected timing and implementation of any repurchases, the completion of remaining procedural requirements relating to the capital reduction, the Company’s capital allocation strategy, potential non-dilutive financing alternatives, strategic capital initiatives, potential M&A activity, market valuation, operating momentum, strategic position, growth prospects and long-term value creation.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, among others, risks relating to the implementation of the proposed share repurchase program, completion of remaining procedural requirements relating to the capital reduction, market volatility, changes in trading liquidity, legal and regulatory restrictions, capital allocation requirements, business performance and other risks described in the Company’s filings with the Securities and Exchange Commission.

The share repurchase program does not require the Company to repurchase any specific number or dollar amount of shares and may be suspended, modified or discontinued at any time. Any repurchases will be made in compliance with applicable securities laws and other legal requirements.

Rezolve Ai undertakes no obligation to update any forward-looking statements, except as required by law.

The expanded relationship builds on a series of agreements announced this year, strengthening Dentsply Sirona’s North American dealer network and giving more customers access to its products and technology.

CHARLOTTE, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — Dentsply Sirona (Nasdaq: XRAY), the world’s largest diversified manufacturer of professional dental products and technologies, today announced an expanded relationship with Midwest Dental Equipment & Supply, an independent, family-owned distributor of dental supplies, equipment, and technology.

Effective November 1, 2026, Midwest Dental will begin offering Dentsply Sirona’s technology portfolio in the United States, building on a relationship that has historically focused on consumables. The expanded relationship increases access to Dentsply Sirona’s digital dentistry solutions through Midwest Dental’s network of sales, service, and technical specialists.

The agreement reflects continued execution against Dentsply Sirona’s commitment to broaden access to its connected technology portfolio by expanding relationships with trusted distribution partners across North America.

Together, these agreements support Dentsply Sirona’s commercial strategy to increase customer access, strengthen coverage in key markets and support adoption of the Company’s connected technology solutions.

Founded in 1988 and headquartered in Wichita Falls, Texas, Midwest Dental Equipment & Supply is the largest independent, family-owned distributor in the Southern U.S. serving dental professionals nationwide, with sales, service, and technical teams on the ground in Texas, Oklahoma, New Mexico, and Arkansas.

“Midwest Dental has built strong relationships across the markets it serves, from independent practices to larger customer groups, making it an important partner as we continue expanding access to connected dentistry,” said Mark Bezjak, Group Vice President, Americas RCO at Dentsply Sirona. “By bringing our technology portfolio to Midwest Dental’s customers, we are extending the reach of a connected ecosystem designed to help practices improve efficiency, simplify workflows and support long-term growth.”

“Our customers trust us to help them make the best technology decisions that are right for their practice,” said Matt LeVasseur, Chief Executive Officer at Midwest Dental Equipment & Supply. “Adding Dentsply Sirona’s technology portfolio allows us to offer the industry’s leading and most complete digital dentistry solutions. When you add support from local service technicians, in-depth training and technical expertise, we’re able to exceed our customers’ expectations. In today’s busy marketplace, it is important for our customers to have an easy, seamless and profitable solution for same-visit crown restorations and Dentsply Sirona’s technology allows Midwest Dental to do that at the highest level”

The Midwest Dental agreement marks Dentsply Sirona’s seventh North American dealer partnership enhancement of 2026, following new technology agreements with Benco Dental Supply Co., The Burkhart Dental Supply Co., Nashville Dental, Inc., The Atlanta Dental Supply Company, and Medline Sinclair, as well as a renewed partnership with Patterson Dental. Together, these agreements support Dentsply Sirona’s commercial strategy to expand customer access, strengthen coverage in key markets and accelerate adoption of the Company’s connected technology solutions.

About Dentsply Sirona

Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information Investors:

Wade Moody
Senior Manager, Investor Relations
Investorrelations@dentsplysirona.com

Contact Information Press:

Marion Par-Weixlberger
Vice President, Public Relations, Corporate Communications & Brand
Publicrelations@dentsplysirona.com 

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market. 
 
“We are excited to welcome BioLife team members to Repligen,” said Olivier Loeillot, President and Chief Executive Officer of Repligen. “BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies. Over the past several months, our teams have worked closely together to develop a thoughtful integration plan, and we are even more excited about the strategic rationale of bringing our organizations together and the value we will create for patients, customers, and shareholders.”
 
BioLife’s products are deeply embedded in the cell therapy workflow and highly complementary to Repligen’s existing offering in this market. BioLife’s differentiated biopreservation media portfolio, led by CryoStor^®, supports 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials. As a combined commercial team, BioLife will benefit from Repligen’s broader global reach, including Asia Pacific, while Repligen will benefit from BioLife’s trusted customer relationships.
 
In connection with the transaction, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash in lieu of any fractional shares of Repligen common stock.
 
Repligen intends to provide additional detail regarding the transaction’s expected impact on Repligen’s 2026 financial outlook in the upcoming third quarter 2026 earnings call.
 
Advisors
Perella Weinberg Partners LP and Goldman Sachs & Co. LLC served as financial advisors and Goodwin Procter LLP served as legal counsel to Repligen. Centerview Partners, LLC served as financial advisor and K&L Gates LLP served as legal counsel to BioLife.
 
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
 
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements regarding the expected benefits of the transaction and Repligen’s ability to recognize such benefits; the anticipated financial impact of the transaction on Repligen; expectations for Repligen’s performance following the transaction; and beliefs and expectations about the cell therapy industry, including its growth, and BioLife’s position as a highly-differentiated cell processing tool leader. Words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and variations of such words and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
 
Repligen Contact: 
Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com